Headlines about Quidel (NASDAQ:QDEL) have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Quidel earned a news impact score of 0.20 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.8392847509797 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several research firms have weighed in on QDEL. CL King raised Quidel from a “neutral” rating to a “buy” rating and set a $52.00 price objective for the company in a report on Thursday, January 4th. Zacks Investment Research cut Quidel from a “hold” rating to a “strong sell” rating in a report on Thursday, December 28th. Canaccord Genuity reaffirmed a “buy” rating and issued a $52.00 price target (up previously from $48.00) on shares of Quidel in a report on Thursday, December 21st. BidaskClub raised Quidel from a “hold” rating to a “buy” rating in a report on Thursday, December 21st. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $50.00 target price on shares of Quidel in a report on Thursday, December 14th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $50.00.
Quidel (NASDAQ:QDEL) traded down $0.18 during mid-day trading on Friday, hitting $45.99. The stock had a trading volume of 95,300 shares, compared to its average volume of 357,501. The company has a quick ratio of 5.68, a current ratio of 6.28 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $1,560.00, a price-to-earnings ratio of -287.44, a PEG ratio of 1.49 and a beta of 1.15. Quidel has a 1-year low of $18.25 and a 1-year high of $47.60.
Quidel (NASDAQ:QDEL) last released its quarterly earnings results on Wednesday, November 1st. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.21). Quidel had a negative return on equity of 2.36% and a negative net margin of 2.33%. The firm had revenue of $50.89 million for the quarter, compared to analyst estimates of $50.47 million. During the same quarter last year, the company earned $0.10 earnings per share. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. equities research analysts forecast that Quidel will post -0.23 earnings per share for the current fiscal year.
In other Quidel news, Director Jack W. Schuler sold 4,000 shares of the firm’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $47.02, for a total value of $188,080.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Douglas C. Bryant sold 12,000 shares of the firm’s stock in a transaction on Friday, December 28th. The shares were sold at an average price of $44.12, for a total value of $529,440.00. Following the completion of the sale, the chief executive officer now owns 286,493 shares in the company, valued at $12,640,071.16. The disclosure for this sale can be found here. Insiders have sold 385,790 shares of company stock worth $15,760,155 over the last 90 days. 22.00% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Quidel (NASDAQ:QDEL) Stock Price” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/13/quidel-qdel-earns-daily-media-sentiment-rating-of-0-20.html.
Quidel Company Profile
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.